Galmed Pharmaceuticals Q1 2025 Earnings Results & Report

Galmed Pharmaceuticals EPS Results

• Actual EPS: -$4.96
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Galmed Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Galmed Pharmaceuticals (NASDAQ:GLMD) is an Israel-based biopharmaceutical company focused on developing therapies for liver, metabolic, inflammatory and fibrotic diseases. The company’s research has centered on orally administered treatments designed to address conditions in which excess fat accumulation, inflammation and tissue fibrosis contribute to disease progression.

Galmed’s principal historical product candidate is aramchol, an investigational fatty acid-bile acid conjugate developed for the treatment of nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH). The compound was studied for its potential to reduce liver fat and fibrosis, although its development has included setbacks in late-stage clinical testing.

The company has also explored additional therapeutic programs, including Amilo-5MER, an oral investigational treatment intended for inflammatory diseases such as ulcerative colitis. Galmed has conducted its research and clinical-development activities internationally, with corporate roots and operations in Israel and clinical work involving patients and research partners in multiple geographies.